COVID-19 natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| Line 13: | Line 13: | ||
*# Non-life-threatening [[pneumonia]] | *# Non-life-threatening [[pneumonia]] | ||
*# Severe [[pneumonia]] with [[Acute respiratory distress syndrome|acute respiratory distress syndrome (ARDS)]] that begins with mild [[Symptom|symptoms]] for 7 - 8 days and progressing to rapid deterioration and [[Acute respiratory distress syndrome|ARDS]] requiring [[advanced life support]] | *# Severe [[pneumonia]] with [[Acute respiratory distress syndrome|acute respiratory distress syndrome (ARDS)]] that begins with mild [[Symptom|symptoms]] for 7 - 8 days and progressing to rapid deterioration and [[Acute respiratory distress syndrome|ARDS]] requiring [[advanced life support]] | ||
*In a study of 44,672 confirmed cases in Mainland China: | |||
**80.9% were reported to have a mild disease | |||
**13.8% were reported to have severe disease with the indication for hospitalization | |||
*In [[symptomatic]] [[Patient|patients]], the clinical features of the [[disease]] usually start within a week, consisting of [[fever]], [[cough]], [[nasal congestion]], [[fatigue]], and other [[Medical sign|signs]] of [[Upper respiratory tract infection|upper respiratory tract infections]].<ref name="VelavanMeyer2020">{{cite journal|last1=Velavan|first1=Thirumalaisamy P.|last2=Meyer|first2=Christian G.|title=The COVID‐19 epidemic|journal=Tropical Medicine & International Health|volume=25|issue=3|year=2020|pages=278–280|issn=1360-2276|doi=10.1111/tmi.13383}}</ref> | *In [[symptomatic]] [[Patient|patients]], the clinical features of the [[disease]] usually start within a week, consisting of [[fever]], [[cough]], [[nasal congestion]], [[fatigue]], and other [[Medical sign|signs]] of [[Upper respiratory tract infection|upper respiratory tract infections]].<ref name="VelavanMeyer2020">{{cite journal|last1=Velavan|first1=Thirumalaisamy P.|last2=Meyer|first2=Christian G.|title=The COVID‐19 epidemic|journal=Tropical Medicine & International Health|volume=25|issue=3|year=2020|pages=278–280|issn=1360-2276|doi=10.1111/tmi.13383}}</ref> | ||
*Disease progression and severity is manifested by [[dyspnea]] and severe [[chest]] [[Symptom|symptoms]] corresponding to [[pneumonia]] in approximately 75% of the [[Patient|patients]].<ref name="GuanNi2020">{{cite journal|last1=Guan|first1=Wei-jie|last2=Ni|first2=Zheng-yi|last3=Hu|first3=Yu|last4=Liang|first4=Wen-hua|last5=Ou|first5=Chun-quan|last6=He|first6=Jian-xing|last7=Liu|first7=Lei|last8=Shan|first8=Hong|last9=Lei|first9=Chun-liang|last10=Hui|first10=David SC|last11=Du|first11=Bin|last12=Li|first12=Lan-juan|last13=Zeng|first13=Guang|last14=Yuen|first14=Kowk-Yung|last15=Chen|first15=Ru-chong|last16=Tang|first16=Chun-li|last17=Wang|first17=Tao|last18=Chen|first18=Ping-yan|last19=Xiang|first19=Jie|last20=Li|first20=Shi-yue|last21=Wang|first21=Jin-lin|last22=Liang|first22=Zi-jing|last23=Peng|first23=Yi-xiang|last24=Wei|first24=Li|last25=Liu|first25=Yong|last26=Hu|first26=Ya-hua|last27=Peng|first27=Peng|last28=Wang|first28=Jian-ming|last29=Liu|first29=Ji-yang|last30=Chen|first30=Zhong|last31=Li|first31=Gang|last32=Zheng|first32=Zhi-jian|last33=Qiu|first33=Shao-qin|last34=Luo|first34=Jie|last35=Ye|first35=Chang-jiang|last36=Zhu|first36=Shao-yong|last37=Zhong|first37=Nan-shan|year=2020|doi=10.1101/2020.02.06.20020974}}</ref> | *Disease progression and severity is manifested by [[dyspnea]] and severe [[chest]] [[Symptom|symptoms]] corresponding to [[pneumonia]] in approximately 75% of the [[Patient|patients]].<ref name="GuanNi2020">{{cite journal|last1=Guan|first1=Wei-jie|last2=Ni|first2=Zheng-yi|last3=Hu|first3=Yu|last4=Liang|first4=Wen-hua|last5=Ou|first5=Chun-quan|last6=He|first6=Jian-xing|last7=Liu|first7=Lei|last8=Shan|first8=Hong|last9=Lei|first9=Chun-liang|last10=Hui|first10=David SC|last11=Du|first11=Bin|last12=Li|first12=Lan-juan|last13=Zeng|first13=Guang|last14=Yuen|first14=Kowk-Yung|last15=Chen|first15=Ru-chong|last16=Tang|first16=Chun-li|last17=Wang|first17=Tao|last18=Chen|first18=Ping-yan|last19=Xiang|first19=Jie|last20=Li|first20=Shi-yue|last21=Wang|first21=Jin-lin|last22=Liang|first22=Zi-jing|last23=Peng|first23=Yi-xiang|last24=Wei|first24=Li|last25=Liu|first25=Yong|last26=Hu|first26=Ya-hua|last27=Peng|first27=Peng|last28=Wang|first28=Jian-ming|last29=Liu|first29=Ji-yang|last30=Chen|first30=Zhong|last31=Li|first31=Gang|last32=Zheng|first32=Zhi-jian|last33=Qiu|first33=Shao-qin|last34=Luo|first34=Jie|last35=Ye|first35=Chang-jiang|last36=Zhu|first36=Shao-yong|last37=Zhong|first37=Nan-shan|year=2020|doi=10.1101/2020.02.06.20020974}}</ref> | ||
Revision as of 22:33, 13 March 2020
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of COVID-19 natural history, complications and prognosis |
|
FDA on COVID-19 natural history, complications and prognosis |
|
CDC on COVID-19 natural history, complications and prognosis |
|
COVID-19 natural history, complications and prognosis in the news |
|
Blogs on COVID-19 natural history, complications and prognosis |
|
Risk calculators and risk factors for COVID-19 natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Natural History, Complications, and Prognosis
Natural History
- The clinical course of the disease consists of three major patterns:[1]
- Mild illness with upper respiratory tract presenting symptoms
- Non-life-threatening pneumonia
- Severe pneumonia with acute respiratory distress syndrome (ARDS) that begins with mild symptoms for 7 - 8 days and progressing to rapid deterioration and ARDS requiring advanced life support
- In a study of 44,672 confirmed cases in Mainland China:
- 80.9% were reported to have a mild disease
- 13.8% were reported to have severe disease with the indication for hospitalization
- In symptomatic patients, the clinical features of the disease usually start within a week, consisting of fever, cough, nasal congestion, fatigue, and other signs of upper respiratory tract infections.[2]
- Disease progression and severity is manifested by dyspnea and severe chest symptoms corresponding to pneumonia in approximately 75% of the patients.[3]
- Pneumonia mostly occurs in the second or third week of a symptomatic disease.
- Signs of the above mentioned pneumonia (viral pneumonia) include decreased oxygen saturation, blood gas deviations, and changes on chest X‐ray and other imaging techniques.
References
- ↑ Heymann, David L; Shindo, Nahoko (2020). "COVID-19: what is next for public health?". The Lancet. 395 (10224): 542–545. doi:10.1016/S0140-6736(20)30374-3. ISSN 0140-6736.
- ↑ Velavan, Thirumalaisamy P.; Meyer, Christian G. (2020). "The COVID‐19 epidemic". Tropical Medicine & International Health. 25 (3): 278–280. doi:10.1111/tmi.13383. ISSN 1360-2276.
- ↑ Guan, Wei-jie; Ni, Zheng-yi; Hu, Yu; Liang, Wen-hua; Ou, Chun-quan; He, Jian-xing; Liu, Lei; Shan, Hong; Lei, Chun-liang; Hui, David SC; Du, Bin; Li, Lan-juan; Zeng, Guang; Yuen, Kowk-Yung; Chen, Ru-chong; Tang, Chun-li; Wang, Tao; Chen, Ping-yan; Xiang, Jie; Li, Shi-yue; Wang, Jin-lin; Liang, Zi-jing; Peng, Yi-xiang; Wei, Li; Liu, Yong; Hu, Ya-hua; Peng, Peng; Wang, Jian-ming; Liu, Ji-yang; Chen, Zhong; Li, Gang; Zheng, Zhi-jian; Qiu, Shao-qin; Luo, Jie; Ye, Chang-jiang; Zhu, Shao-yong; Zhong, Nan-shan (2020). doi:10.1101/2020.02.06.20020974. Missing or empty
|title=(help)